Recalls involving the name-brand heartburn drug Zantac (ranitidine) and similar generic versions culminated April 1 in the FDA asking drug manufacturers to immediately withdraw all prescription and over-the-counter ranitidine products, including generic ones, from the U.S. market due to concerns that they may contain toxic N-Nitrosodimethylamine (NDMA).